BEAM vs RARE · rev $32.2M vs rev $350.0M
Beam Therapeutics Inc (BEAM) versus Ultragenyx (RARE) — a side-by-side from cached financials, not a winner call.
Beam Therapeutics Inc (BEAM) is a biotechnology company listed on US.
Ultragenyx (RARE) is a biotechnology company listed on US.
Latest reported BEAM revenue for 2026-06-30 was $32.2M. Net income was -$217.0M. Revenue was up 1.5% from 2026-03-31 to 2026-06-30. BEAM currently screens at market cap $2.01B.
Latest reported RARE revenue for 2026-06-30 was $350.0M. Net income was -$277.0M. RARE currently screens at market cap $2.79B.
BEAM currently screens at market cap $2.01B. RARE currently screens at market cap $2.79B.
Not investment advice. Open the BEAM and RARE stock pages for the full models.
Not investment advice.